Altimmune (ALT) vs Eupraxia Pharmaceuticals (EPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eupraxia Pharmaceuticals (EPRX) has outperformed Altimmune (ALT) over the past year, gaining 29.2% versus a loss of 32.3%. Altimmune is the larger company by market cap ($499.9 million vs $493.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | EPRX |
|---|---|---|
| Share price | $2.57 | $7.47 |
| Market cap | $499.93M | $493.57M |
| 1-day change | -3.38% | -3.98% |
| YTD return | -26.32% | +3.05% |
| 1-year return | -32.32% | +29.24% |
| 5-year return | -77.85% | — |
| EPS (TTM) | $-0.76 | $-1.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $9.32 |
| 52-week low | $2.55 | $5.25 |
| Distance from 52-week high | -60.09% | -19.85% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +565.73% | +118.88% |
| Average volume | 4.18M | 567.95K |
| Shares outstanding | 194.52M | 66.07M |
| Employees | 57 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EPRX has outperformed ALT by 61.6 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Eupraxia Pharmaceuticals
EPRX stock →Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Health Care · Pharmaceuticals and Biotechnology · 49 employees
ALT vs EPRX FAQ
Which is bigger, Altimmune or Eupraxia Pharmaceuticals?
Altimmune (ALT) is larger, with a market capitalization of $499.93M compared with $493.57M for Eupraxia Pharmaceuticals (EPRX).
Which stock has performed better over the past year, ALT or EPRX?
EPRX returned +29.24% over the past 12 months, compared with -32.32% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Eupraxia Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Altimmune and Pharmaceuticals and Biotechnology for Eupraxia Pharmaceuticals.